Clinical trial · Interventional
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Azacitidine Plus PD-1 Therapy for Relapsed/Refractory Hodgkin Lymphoma
NCT06190067CI-TRIAL-00073391recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Classic Hodgkin Lymphoma | Classic Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Relapsed Classic Hodgkin Lymphoma | Classic Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Azacitidine Plus PD-1 therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Azacitidine Plus PD-1 therapy
- description
- Patients were treated by Azacitidine plus PD-1 therapy
- interventionNames
- Drug: Azacitidine Plus PD-1 therapy
Primary outcomes (1)
- measure
- Overall Response Rate (ORR)
- timeFrame
- 1 year
- description
- ORR was defined as the proportion of patients who achieved CR or PR as their best response
Secondary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- through study completion, an average of 2 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification. * Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted. * Patient is willing and able to adhere to the study visit schedule and other protocol requirements. * Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below). * Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL. * Anticipated life expectancy at least 3 months. Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. * Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.